Cavanaugh Sarah
Known title: SVP of Corp Affairs & Admin.CIK: 0001709113
Associated companies
Transaction History
| CLDX | ▼ Sell | Open Market | 20,853 | $703K | 5/30/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 10,750 | $30K | 5/30/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 10,103 | $91K | 5/30/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 1,355 | $49K | 8/18/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 1,355 | $12K | 8/18/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 31,312 | $87K | 8/17/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 31,312 | $1.2M | 8/17/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 1,857 | $17K | 12/8/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 5,466 | $57K | 12/8/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 7,323 | $293K | 12/8/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 5,018 | $45K | 11/1/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 938 | $3K | 11/1/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 4,302 | $190K | 11/1/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 901 | $39K | 11/1/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 2,120 | $88K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.